ROCKLAND, Mass., April 6, 2015 /PRNewswire/ -- EMD Serono, the U.S. biopharmaceuticals subsidiary of Merck KGaA, Darmstadt, Germany, today announced the launch of the 11th edition of the EMD Serono Specialty Digest at the 27th Annual Meeting of The Academy of Managed Care Pharmacy (AMCP) in San Diego, CA. The Digest is an educational resource that provides market data on health plans’ management of specialty pharmaceuticals in 2014 and identifies common trends occurring across plans. The Digest is available to those who request a copy at http://www.specialtydigest.emdserono.com.
The 11th edition of the EMD Serono Specialty Digest includes data from 70 commercial health plans across the country, representing more than 100 million covered lives. This year’s Digest has been enhanced to reflect current opportunities, challenges, and solutions to specialty drug management, including new topics regarding benefit design, medical provider reimbursement and management, and analysis of the top therapy categories driving specialty drug costs (oncology, immune modulators, multiple sclerosis and hepatitis C).
The results of this year’s Digest raise important questions regarding specialty drug cost management. The recent focus of payer management has been on member cost share, specialty pharmacy network contract rate, and traditional utilization management. This year’s Digest highlights a new focus on coordinating strategies across the pharmacy and medical benefits, directing members to the lowest cost site of care, measuring the value of therapy, realigning provider incentives, educating members about their health care choices, and reducing administrative burden through the adoption of vendor partnerships and new technologies.
“The 11th edition of the EMD Serono Specialty Digest highlights some important trends in specialty drug management today as well as expectations for management in the future,” said Allene Diaz, Senior Vice President, Managed Markets, EMD Serono. “As a leader in specialty care, we are committed to partnering with our customers to improve patient outcomes and trust that the Specialty Digest will provide valuable information on how to attain this goal.”
The EMD Serono Specialty Digest was developed in 2004 to provide a comprehensive reference for managed care decision makers regarding the management of specialty products. Over the past eleven years, health plans, Pharmacy Benefit Managers (PBMs), employers, specialty pharmacies, and pharmaceutical companies have relied on the Digest to identify current and future trends in the management of specialty pharmaceuticals.
Findings are available in the full text of the EMD Serono Specialty Digest, at http://www.specialtydigest.emdserono.com.
About EMD Serono
EMD Serono, a subsidiary of Merck KGaA, Darmstadt, Germany, is a leading US biopharmceutical company focused exclusively on specialty care. For more than 40 years, EMD Serono has integrated cutting-edge science, innovative products and devices, and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in neurology, oncology, immunology and immuno-oncology. Today, EMD Serono has more than 1,100 employees around the country with commercial, clinical and research operations based in the company’s home state of Massachusetts.
For more information, please visit www.emdserono.com
Merck KGaA, Darmstadt, Germany
Merck KGaA of Darmstadt, Germany, is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses Biopharmaceuticals, Consumer Health, Allergopharma, Biosimilars, Life Science and Performance Materials and generated sales of 11.3 billion in 2014. Around 39,000 employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck KGaA, Darmstadt, Germany, is the world’s oldest pharmaceutical and chemical company since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck KGaA, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.
Cory Tromblee
Phone: 781.681.2393
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emd-serono-launches-11th-edition-of-the-emd-serono-specialty-digest-at-annual-meeting-of-the-academy-of-managed-care-pharmacy-300061080.html
SOURCE EMD Serono
Help employers find you! Check out all the jobs and post your resume.
